Hematological Neoplasms
Tecartus (brexucabtagene autoleucel), developed by Kite Pharma (now part of Gilead Sciences), is one such therapy that has gained significant attention for its efficacy in treating certain types of lymphoma and leukemia.
22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient In July 2017, 58-year-old Ms. M was diagnosed with multiple myeloma. After receiving treatments at the best hospital in Thailand, including PCD, DVD, bortezomib and lenalidomide, autologous hematopoietic stem cell transplantation. The disease rapidly relapsed. Local doctors informed Read More
On July 24, 2020, the US Food and Drug Administration (FDA) granted accelerated approval to Tecartus (brexucabtagene autoleucel), a groundbreaking CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). Subsequently, on October 1, 2021, the FDA expanded the approval of Tecartus to include the treatment of adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL).
Nature Communications | Chinese Medical Team Innovates CAR-T Therapy to Bring New Hope for AML Treatment In the field of hematological malignancies, the treatment of acute myeloid leukemia (AML) has long been a challenge in the medical community. Particularly for relapsed or refractory patients, the limitations of traditional treatments have increased the urgent need for Read More
**Chinese Medical Team Research: 64.6% Complete Remission Rate, Over Half of Patients Progression-Free for More Than Two Years! Targeted Therapy Combined with Chemotherapy is Safe and Effective as First-Line Treatment for Lymphoma** Peripheral T-cell lymphoma (PTCL) is a group of highly aggressive and heterogeneous diseases with poor prognosis. The standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, Read More
### Overcoming Challenges and Embracing New Life! – Breakthrough Progress of Eque-cel in the Treatment of Refractory Multiple Myeloma In the treatment of multiple myeloma (MM), how do we find new breakthroughs for patients who have not achieved complete remission (CR) after multiple rounds of chemotherapy? Research by Chinese medical professors has provided an exciting Read More
In early June 2024, the results of a Phase I clinical trial for the CD7-CAR-T product PA3-17 in the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (r/r T-ALL/LBL) were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
